In certain situations more protein in diet is required. Achieving this goal when animal sources are not welcome is not that easy, specially when dairy intolerance/allergies are present. We just designed a vegetarian protein with the highest profile of amino acids and biodisponibility. It presents the maximum PDCAAS equal to milk but free of allergens. […]
In the fourth edition of 2017, the spanish magazine Nutrición Hospitalaria summarizes the content and spechees of the Madrid Complutense University Nutrition Conference. This year David Manrique reviewed the clinical use of formulations for the oral use of butyric acid in pathologies with intestinal affectation. This is the link to the whole article.
The human intestine houses trillions of commensal bacteria (gut microbiota) dominated by nearly 800 different species. “Healthy” gut microbiota supports epithelial cell health, nutrient metabolism and breakdown, and indirect mucosal defense against pathogenic bacteria. Gut microbiota ferment non-digestible polysaccharides to yield short-chain fatty acids (SCFA), acetate, propionate, and butyrate. Butyrate is the most dynamic SCFA […]
Butyric acid is the main source of energy for colonocytes. Many intestinal diseases are characterised by reduced concentrations of butyric acid in the colon.
Here you can download our work in #NutricionPractica 2017, held in Madrid 5-6 April. PDF: Formulación de nuevo complemento alimenticio de ácido butírico microencapsulado
You can download our work at Sepyp 2017, oral communication titled: Enteric Release Butyric Acid: Innovation in oral formulation. Objetives: Formulate and develop a nutritional supplement that ensures the enteric release of butyric acid and that presents organoleptic characteristics that do not hinder the therapeutic adherence. Metodología: Electro-hydrodynamic technology of monodisperse microcapsules, using tributyrin as […]
The research and development of BUTYCAPS on the spanish Canal Sur Radio. David Manrique was interviewed on saturday the 18th of February about the technological process of BUTYCAPS and the uses of tributyrin, a triglyceride of butyric acid, for intestinal health. Go to the minute 46 to listen to the whole interview Thanks!
We are glad to share with you our work in the 2017 International Congress on Orphan Drugs and Rare Diseases. ‘Formulation of a Nutritional Supplement based on Microencapsulated Tributyrin for Oral Supply of Butyric Acid in Short Bowel Syndrome’ We are sorry it’s in spanish…
In the last decade we have witnessed an exponential increase in the therapeutic use of probiotics and prebiotics for both acute and chronic gastrointestinal pathologies. The use of postbiotics such as butyric acid is a new tool in gastroenterology and nutrition.
The Spanish Association of Irritable Bowel Syndrome (IBS) yesterday echoed the release of BUTYCAPS. The information is detailed below. We are sorry it is only in spanish… http://www.aesii.es/2016/11/nota-de-prensa-butycaps.html